Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Non-Randomized, Multi-Center Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT03531255 is registered in ClinicalTrials.gov with Apellis Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03531255
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03531255 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Non-Randomized, Multi-Center Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
Lead sponsor
Apellis Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
August 27, 2018
Completion date
May 19, 2026
Enrollment
137 (actual)
Sites
62

Conditions

As the registry lists them; a condition with its own page is linked.

pnh